1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Liver Disease Newco Alentis Raises CHF12.5m Series A

 
• By Mike Ward

A syndicate of European VCs commits CHF12.5m to Alentis Therapeutics a Swiss-French start-up with a discovery platform focusing on liver diseases. Lead program is a humanized monoclonal antibody targeting liver fibrosis and hepatocellular carcinoma.

Liver cancer, CT scan upper abdomen.
Advanced liver disease and cancer are major clinical challenges

Swiss venture capital firms BioMedPartners and BB Pureos Bioventures have co-led a CHF12.5m ($12.3m) series A round in Alentis Therapeutics, a Swiss-French newco, that is looking to develop novel therapeutics in advanced liver disease and cancer. Other investors in the syndicate are BPI France, Schroder Adveq and the German High-Tech Gründerfonds. Markus Ewert, formerly CBO at Ablynx NV, has been appointed CEO of the new company, which will be headquartered in Basel, Switzerland with a subsidiary in Strasbourg, France and a branch in Germany.

Incubated for the past 18 months by SATT Connectus, the tech transfer accelerator associated with the Alsace region, Alentis is underpinned by research of scientific co-founder, Thomas Baumert, at the University of Strasbourg, the Inserm Institute of Viral and Liver Disease, the Laboratory of Excellence HepSYS and the Institut

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.